RY 174.38 -0.6382% SHOP 153.13 0.4592% TD 81.72 -0.475% ENB 64.56 -0.6922% BN 84.69 -1.2937% TRI 235.95 1.3226% CNQ 45.8 0.3286% CP 112.58 1.0592% CNR 150.84 1.4733% BMO 144.13 0.2365% BNS 73.95 -0.5246% CSU 4494.0049 1.1951% CM 91.42 0.4947% MFC 43.94 -0.6557% ATD 76.54 0.7105% NGT 60.17 -0.9547% TRP 68.2 0.191% SU 56.95 -0.2627% WCN 257.0 0.1715% L 183.43 1.2698%
Last update at 2025-01-22T19:23:00Z
Medexus Pharmaceuticals Announces C$10 Million Bought-Deal Public Offering of Units
Tue 05 Sep 23, 10:41 PMMedexus Expects Record Revenue for Fiscal Year 2023 and Provides Business Update
Tue 11 Apr 23, 11:25 AMMedexus Announces New License Deal for Topical Terbinafine
Wed 22 Mar 23, 11:20 AMMedexus Announces US$58.5 million in New Credit Facilities
Wed 08 Mar 23, 10:00 PMMedexus Welcomes Two New Board Members
Mon 06 Feb 23, 10:00 PMMedexus Secures Public Reimbursement for Cuvposa® in Quebec
Wed 01 Feb 23, 10:00 PM| Breakdown | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 |
| Income before tax | 0.11M | -5.04100M | -3.82000M | -31.50100M | -5.18756M |
| Minority interest | - | - | - | - | - |
| Net income | -0.21400M | 1.22M | -2.87900M | -28.26400M | -4.39712M |
| Selling general administrative | 27.86M | 36.86M | 34.52M | 19.28M | 11.77M |
| Selling and marketing expenses | 10.58M | 11.39M | 9.51M | 16.89M | 17.16M |
| Gross profit | 59.51M | 60.04M | 37.93M | 42.01M | 29.44M |
| Reconciled depreciation | 5.81M | 6.08M | 6.14M | 5.98M | 3.71M |
| Ebit | 10.76M | 6.52M | -13.93606M | -1.19117M | -3.54961M |
| Ebitda | 18.59M | 14.57M | -6.23100M | 6.71M | 1.71M |
| Depreciation and amortization | 7.83M | 8.05M | 7.71M | 7.90M | 5.26M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 10.79M | 7.61M | -14.99600M | -1.37600M | -5.41249M |
| Other operating expenses | 100.27M | 99.61M | 89.08M | 78.93M | 53.47M |
| Interest expense | 13.36M | 13.61M | 12.22M | 9.82M | 6.44M |
| Tax provision | 0.32M | -6.26200M | -0.94100M | -3.23700M | -0.79044M |
| Interest income | - | 12.65M | 11.18M | 0.00300M | 0.21M |
| Net interest income | -13.36400M | -13.60600M | -12.22300M | -9.81600M | -7.40093M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.32M | -6.26200M | -0.94100M | -3.23700M | -0.79044M |
| Total revenue | 113.05M | 108.10M | 76.70M | 79.66M | 52.43M |
| Total operating expenses | 46.73M | 51.55M | 50.30M | 41.27M | 30.48M |
| Cost of revenue | 53.54M | 48.06M | 38.77M | 37.66M | 22.99M |
| Total other income expense net | 0.68M | 0.08M | 20.78M | -22.41600M | 3.25M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -0.21400M | 1.22M | -2.87900M | -28.26400M | -4.39712M |
| Net income applicable to common shares | - | 1.22M | -2.87900M | -28.26400M | -4.70100M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 |
| Total assets | 155.73M | 161.33M | 139.22M | 148.51M | 122.81M |
| Intangible assets | 64.14M | 70.37M | 76.56M | 76.36M | 69.49M |
| Earning assets | - | - | - | - | - |
| Other current assets | 2.30M | 2.29M | 1.28M | 1.67M | 1.11M |
| Total liab | 125.41M | 138.88M | 121.43M | 130.50M | 98.53M |
| Total stockholder equity | 30.32M | 22.45M | 17.79M | 18.02M | 24.28M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 2.70M | 7.38M | 3.89M | 2.04M | 1.78M |
| Common stock | 76.39M | 69.01M | 68.69M | 66.69M | 44.76M |
| Capital stock | 76.39M | 69.01M | 68.69M | 66.69M | 42.19M |
| Retained earnings | -64.24200M | -64.02800M | -65.24900M | -62.37000M | -34.10600M |
| Other liab | - | 28.01M | 33.51M | 56.26M | 35.73M |
| Good will | 10.28M | 10.28M | 10.69M | 10.65M | 10.06M |
| Other assets | - | 6.81M | 1.64M | 2.13M | 2.12M |
| Cash | 5.25M | 13.07M | 10.02M | 18.70M | 5.23M |
| Cash and equivalents | - | 13.07M | 10.02M | 18.70M | 5.23M |
| Total current liabilities | 66.23M | 83.50M | 48.11M | 39.94M | 34.16M |
| Current deferred revenue | 40.03M | - | - | - | - |
| Net debt | 44.64M | 57.01M | 44.84M | 26.17M | 33.58M |
| Short term debt | 15.74M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Short long term debt | 15.74M | 42.71M | 15.05M | 10.57M | 10.19M |
| Short long term debt total | 49.90M | - | - | 34.30M | 28.61M |
| Other stockholder equity | 12.01M | 6.16M | 3.97M | 4.20M | 6.58M |
| Property plant equipment | - | 0.90M | 1.22M | 0.80M | 1.10M |
| Total current assets | 72.50M | 72.97M | 49.11M | 58.57M | 39.73M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | -58.20700M | -69.45900M | -68.99700M | -55.54700M |
| Short term investments | - | - | - | - | - |
| Net receivables | 24.03M | 22.38M | 14.41M | 18.83M | 14.96M |
| Long term debt | 34.15M | 27.38M | 39.82M | 34.30M | 28.62M |
| Inventory | 30.77M | 22.85M | 21.35M | 14.67M | 14.08M |
| Accounts payable | 7.75M | 33.41M | 12.05M | 14.86M | 8.90M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 6.17M | - | - | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | - | - | 1.64M | 2.13M | 2.12M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 83.24M | 88.36M | 90.11M | 89.94M | 82.77M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | - | 27.38M | 39.82M | 34.30M | 28.61M |
| Breakdown | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 |
| Investments | -3.47800M | -1.72100M | -8.19600M | -11.70400M | -28.57072M |
| Change to liabilities | - | 4.75M | 3.60M | 4.62M | 4.95M |
| Total cashflows from investing activities | - | -1.72100M | -8.19600M | -11.70700M | -30.32000M |
| Net borrowings | - | 10.73M | 3.73M | -0.01900M | 19.67M |
| Total cash from financing activities | -23.04800M | 6.41M | 0.66M | 18.68M | 14.60M |
| Change to operating activities | - | -9.79100M | 3.35M | -0.92900M | 0.13M |
| Net income | -0.21400M | 1.22M | -2.87900M | -28.26400M | -4.39712M |
| Change in cash | -7.81400M | 3.05M | -8.68600M | 13.47M | -15.35820M |
| Begin period cash flow | 13.07M | 10.02M | 18.70M | 5.23M | 20.59M |
| End period cash flow | 5.25M | 13.07M | 10.02M | 18.70M | 5.23M |
| Total cash from operating activities | 18.71M | -1.44400M | -1.18000M | 5.04M | -1.62248M |
| Issuance of capital stock | 7.61M | 0.00000M | 0.00000M | 22.64M | 0.00000M |
| Depreciation | 5.81M | 6.08M | 6.14M | 5.98M | 3.71M |
| Other cashflows from investing activities | - | -1.35900M | -0.48200M | 0.00300M | 0.22M |
| Dividends paid | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Change to inventory | -6.75300M | -1.98700M | -6.66000M | -0.00900M | 1.00M |
| Change to account receivables | -1.67700M | -8.23600M | 4.43M | -3.50500M | -7.25779M |
| Sale purchase of stock | - | - | 0.00000M | 22.64M | -2.63574M |
| Other cashflows from financing activities | -3.47800M | 31.13M | 0.83M | -3.58300M | 17.55M |
| Change to netincome | - | 6.52M | -9.17600M | 27.14M | 0.63M |
| Capital expenditures | 0.27M | 0.36M | 7.71M | 10.76M | 0.84M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 2.34M | -15.26200M | 4.73M | 0.18M | -1.49133M |
| Stock based compensation | 0.47M | 1.22M | 1.88M | 1.27M | 1.48M |
| Other non cash items | 10.61M | 11.56M | -10.11800M | 29.11M | -0.03455M |
| Free cash flow | 18.45M | -1.80600M | -8.89400M | -5.71700M | -2.46439M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (CAD) | Price (CAD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MDP Medexus Pharmaceuticals Inc |
0.87 21.80% | 4.86 | 36.17 | 13.02 | 0.51 | 1.18 | 0.71 | 4.26 |
| BHC Bausch Health Companies Inc |
0.46 4.30% | 11.17 | - | 2.23 | 0.50 | 18.74 | 2.56 | 9.13 |
| CURA Curaleaf Holdings Inc. |
-0.045 2.11% | 2.08 | - | 138.89 | 1.62 | 1.66 | 1.73 | 10.18 |
| TLRY Tilray Inc |
-0.03 1.78% | 1.66 | - | 1000.00 | 2.17 | 0.36 | 1.69 | -2.299 |
| CRON Cronos Group Inc |
-0.01 0.36% | 2.76 | - | - | 10.18 | 0.70 | 0.02 | -1.9458 |
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Trecondyv, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical revolutionary treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Toronto, Canada.
10 King Street East, Toronto, ON, Canada, M5C 1C3
| Name | Title | Year Born |
|---|---|---|
| Mr. Kenneth d'Entremont | CEO & Director | NA |
| Mr. Marcel Konrad | Chief Financial Officer | 1976 |
| Mr. Michael David Adelman | Gen. Mang., U.S. Operations | 1971 |
| Ms. Tina Byers CFA | Exec. of Investor Relations | NA |
| Mr. Ian C. Wildgoose Brown | Gen. Counsel & Corp. Sec. | NA |
| Mr. Bill Poncy | Sr. VP of Commercial Operations - United States | NA |
| Mr. Brian Peters | VP of Sales & Marketing - United States | NA |
| Mr. Richard Labelle | Chief Operating Officer | NA |
| Mr. Ian C. Wildgoose Brown | General Counsel & Corporate Secretary | NA |
| Mr. Brendon Buschman | Chief Financial Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...